Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

USA News Group News Commentary
Issued on behalf of Oncolytics Biotech Inc.

VANCOUVER, BC, June 30, 2025 /CNW/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a new generation of biotechs is stepping up—including Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC.TO), Cellectar Biosciences, Inc. (NASDAQ:CLRB), Intensity Therapeutics, Inc. (NASDAQ:INTS), Accuray Incorporated (NASDAQ:ARAY), and Erasca, Inc. (NASDAQ:ERAS).